Interestingly, anti-Lair1 antibody treatment was effective in tumors resistant to chemotherapy, radiation, and aPD-1 therapies, highlighting its potential in targeting immune checkpoints relevant to M2-like TAMs, which may be a suitable strategy for cold cancers like glioma that contain more M2-like TAMs and fewer T cells. This evidence concerns the gene LAIR1 and glioma.